NASDAQ · DTSQ
Financial Services · Financial - Conglomerates
$11.58
Up+$0.03 (+0.26%)
Updated Nov 5, 2026, 7:43 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DTSQ
1M range · 7 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
DTSQ closed at $11.56 after 7 trading sessions, up 0.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $11.557 | $11.57 | $11.555 | $11.555 | 29 |
| Oct 27, 2026 | $11.55 | $11.55 | $11.531 | $11.531 | 6 |
| Oct 26, 2026 | $11.55 | $11.55 | $11.55 | $11.55 | 109 |
| Oct 21, 2026 | $11.5793 | $11.58 | $11.57 | $11.58 | 6.01K |
| Oct 19, 2026 | $11.505 | $11.505 | $11.505 | $11.505 | 112 |
| Oct 9, 2026 | $11.4201 | $11.4201 | $11.4201 | $11.4201 | 333 |
| Oct 8, 2026 | $11.58 | $11.58 | $11.42 | $11.48 | 75.86K |
The latest Smart Investors Daily articles mentioning DTSQ.
Company
Market Activity
Research & News
DTSQ research
Company profile and research snapshot.
DT Cloud Star Acquisition Corp is a blank check company.
Consensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jul 20, 2026
DT Cloud Star Acquisition Corporation (NASDAQ:DTSQU, DTSQ, DTSQR))) (the "Company") a newly organized blank check company incorporated in the Cayman Islands as a business company, today announced that on July
Yahoo · Feb 4, 2026
SANTA ANA, CALIFORNIA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- PrimeGen US, Inc. (“PrimeGen US" or the "Company”), a pioneering biotech company advancing innovative stem cell and exosome therapies, today announced it has entered into a definitive business combination agreement dated as of February 2, 2026 (the "Business Combination Agreement") with DT Cloud Star Acquisition Corporation (“DT Cloud Star”), a publicly traded special purpose acquisition company (Nasdaq: DTSQ). The transaction implies an e
Benzinga · Feb 4, 2026
Benzinga · Feb 4, 2026
PrimeGen US, Inc. ("PrimeGen US" or the "Company"), a pioneering biotech company advancing innovative stem cell and exosome therapies, today announced it has entered into a definitive business combination
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DTSQ.
